ATE390920T1 - Lipase inhibitoren zur behandlung von dyspepsia - Google Patents

Lipase inhibitoren zur behandlung von dyspepsia

Info

Publication number
ATE390920T1
ATE390920T1 AT01980222T AT01980222T ATE390920T1 AT E390920 T1 ATE390920 T1 AT E390920T1 AT 01980222 T AT01980222 T AT 01980222T AT 01980222 T AT01980222 T AT 01980222T AT E390920 T1 ATE390920 T1 AT E390920T1
Authority
AT
Austria
Prior art keywords
dyspepsia
treatment
lipase inhibitors
lipase
inhibitors
Prior art date
Application number
AT01980222T
Other languages
English (en)
Inventor
Christine Feinle-Bisset
Michael Fried
Hans Lengsfeld
Thomas Rades
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE390920T1 publication Critical patent/ATE390920T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01980222T 2000-08-09 2001-07-28 Lipase inhibitoren zur behandlung von dyspepsia ATE390920T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00117088 2000-08-09

Publications (1)

Publication Number Publication Date
ATE390920T1 true ATE390920T1 (de) 2008-04-15

Family

ID=8169476

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01980222T ATE390920T1 (de) 2000-08-09 2001-07-28 Lipase inhibitoren zur behandlung von dyspepsia

Country Status (17)

Country Link
US (1) US6534539B2 (de)
EP (1) EP1311260B1 (de)
JP (2) JP4727901B2 (de)
KR (1) KR100494245B1 (de)
CN (1) CN1323661C (de)
AR (1) AR030132A1 (de)
AT (1) ATE390920T1 (de)
AU (2) AU1212002A (de)
BR (1) BR0113101A (de)
CA (1) CA2417607C (de)
DE (1) DE60133470T2 (de)
DK (1) DK1311260T3 (de)
ES (1) ES2304132T3 (de)
MX (1) MXPA03001182A (de)
PT (1) PT1311260E (de)
WO (1) WO2002011719A2 (de)
ZA (1) ZA200300845B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1803714A1 (de) * 2005-12-27 2007-07-04 KRKA, tovarna zdravil, d.d., Novo mesto Verfahren zur Herstellung kristalliner Formen von Orlistat
US8309107B2 (en) * 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
US20140116916A1 (en) * 2012-10-31 2014-05-01 2294719 Ontario Limited Therapy for Constipation
WO2014104871A1 (en) * 2012-12-24 2014-07-03 N.V. Nutricia Method for improving postprandial fat digestion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
AU759388B2 (en) 1998-08-14 2003-04-10 Cheplapharm Arzneimittel Gmbh Pharmaceutical compositions containing lipase inhibitors and chitosan
WO2000009122A1 (en) 1998-08-14 2000-02-24 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors

Also Published As

Publication number Publication date
KR100494245B1 (ko) 2005-06-13
DE60133470D1 (de) 2008-05-15
AU2002212120B2 (en) 2006-05-11
MXPA03001182A (es) 2003-06-30
WO2002011719A3 (en) 2002-06-20
CN1446087A (zh) 2003-10-01
EP1311260B1 (de) 2008-04-02
CA2417607A1 (en) 2002-02-14
EP1311260A2 (de) 2003-05-21
US20020040049A1 (en) 2002-04-04
JP2008120821A (ja) 2008-05-29
PT1311260E (pt) 2008-05-02
DE60133470T2 (de) 2009-05-07
JP4850821B2 (ja) 2012-01-11
DK1311260T3 (da) 2008-06-23
WO2002011719A2 (en) 2002-02-14
ES2304132T3 (es) 2008-09-16
CA2417607C (en) 2008-01-29
CN1323661C (zh) 2007-07-04
JP4727901B2 (ja) 2011-07-20
US6534539B2 (en) 2003-03-18
AU1212002A (en) 2002-02-18
BR0113101A (pt) 2003-06-24
ZA200300845B (en) 2004-04-30
AR030132A1 (es) 2003-08-13
KR20030029811A (ko) 2003-04-16
JP2004505914A (ja) 2004-02-26

Similar Documents

Publication Publication Date Title
DE60035378D1 (de) Gerät zur Behandlung von Bandscheiben
EP1324780A4 (de) Methoden zur behandlung von herzarrhythmie
DE60103137D1 (de) Impstoff zur behandlung von atherosclerosis
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE247117T1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
EP1482962A4 (de) Verfahren zur behandlung von trx-vermittelten erkrankungen
ATE451921T1 (de) Phenylindole zur behandlung von hiv
ATE323661T1 (de) Behandlung von mineralischen stoffen
DE69934877D1 (de) Biochanin-angereicherter extrakt zur behandlung von estrogenabhängigen erkrankungen
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
EP1416953A4 (de) Verfahren zur behandlung von leberfibrose
ATE279386T1 (de) Retinoide zur behandlung von emphysem
DE60114439D1 (de) Verfahren zur antimikrobiellen behandlung von fasermaterialien
DE60223688D1 (de) Verfahren zur behandlung von multiplem myelom
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE60035326D1 (de) Verfahren zur Behandlung von Abwasser
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60104791D1 (de) Cyclobutendion-Derivate zur Behandlung von Artherosclerose

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1311260

Country of ref document: EP